Connor MJ, Khoo V, Watson V, Ahmed HU. Radical treatment without cure: decision-making in oligometastatic prostate cancer. Eur Urol. 2021 Apr;79(4):558-60. doi: 10.1016/j.eururo.2021.01.029
Du XL, Parikh RC, Lairson DR, Giordano SH, Cen P. Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Med Oncol. 2013 Mar;30(1):440. doi: 10.1007/s12032-012-0440-4
Codony-Servat J, Garcia-Albeniz X, Pericay C, Alonso V, Escudero P, Fernandez-Martos C, Gallego R, Martinez-Cardus A, Martinez-Balibrea E, Maurel J. Soluble FAS in the prediction of benefit from cetuximab and irinotecan for patients with advanced colorectal cancer. Med Oncol. 2013 Mar;30(1):428. doi: 10.1007/s12032-012-0428-0
DiBenedetti DB, Gondek K, Sagnier PP, Kubin M, Keininger D, Marquis P. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol. 2005 Sep 1;48(3):503-11.
Robertson KS, Hawe E, Miller GJ, Talmud PJ, Humphries SE, Northwick Park Heart Study II . Northwick Park Heart Study II. Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta. 2003;1639(3):203-12.
Overland GB, Vatten L, Rhodes T, DeMuro C, Jacobsen G, Vada K, Angelsen A, Girman CJ. Lower urinary tract symptoms, prostate volume and uroflow in Norwegian community men. Eur Urol. 2001 Jan 1;39(1):36-41.